A Bidirectional Cohort Study of COMMD10 Expression in Tumor Tissues for Predicting Radiosensitivity

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Dec 3, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a potential marker called COMMD10, which may help predict how sensitive different types of tumors are to radiotherapy, a common treatment for cancer. Many patients with malignant tumors undergo radiotherapy, but some tumors do not respond well to it. The researchers want to see if low levels of COMMD10 in tumor tissues can indicate whether a patient will benefit from radiation treatment or if they might need alternative therapies. By finding a reliable way to predict this, the aim is to improve patient outcomes and quality of life.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with specific types of cancer, including nasopharyngeal, lung, breast, stomach, and several others. Participants will need to agree to receive radiotherapy and have measurable tumor lesions. Those with certain health conditions or who cannot undergo radiotherapy will not be eligible. If you join this study, you can expect to contribute to important research that could help tailor cancer treatments based on individual tumor characteristics.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least 18 years old;
• • 2. Voluntarily sign informed consent;
• • 3. Nasopharyngeal carcinoma, head and neck tumor, lung cancer, breast cancer, stomach cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, bile duct cancer, cervical cancer, prostate cancer confirmed by pathology;
• • 4. Measurable tumor lesions according to RECIST v1.1 criteria;
• • 5. Patients with radiation therapy indications and voluntarily accept radiotherapy;
• • 6. ECOG PS score: 0/1.
• Exclusion Criteria:
• • 1. There are contraindications to radiotherapy;
• • 2. Pathological sections could not be obtained;
• • 3. Presence of metal metabolism-related diseases such as Wilson's disease;
• • 4. Merge other tumors (has cured basal cell or squamous cell cancer, and cervical cancer in situ except 5);
• • 5. Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. "For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor health status, uncontrolled diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness;"
• • 6. The investigator judged that he was not suitable to participate in the study.